All Outputs (2)

Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1 (2016)
Journal Article
Singh, S., Rajendran, R., Kuroda, K., Isogai, E., Krstic-Demonacos, M., & Demonacos, C. (2016). Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1. Journal of Cancer Metastasis and Treatment, 2, 268-276. https://doi.org/10.20517/2394-4722.2016.42

Aim: The aim of the study is to investigate the impact of the cytochrome P450 2E1, which is the most efficient CYP450 family member in generating reactive oxygen species (ROS), on cellular energy metabolism of breast cancer cells and therefore the... Read More about Oxidative stress and breast cancer biomarkers : the case of the cytochrome P450 2E1.

Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Mutti, L., Krstic- Demonacos, M., Cappello, A., …Lisanti, M. (2016). Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 7(23), 34084-34099. https://doi.org/10.18632/oncotarget.9122

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone... Read More about Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.